The study covered in this summary was published as a preprint on ssrn.com and has not yet been peer reviewed.
Key Takeaway
-
Researchers observed that PIK3CA mutation was significantly associated with a lower pathologic complete response rate in patients with HER2-positive breast cancer who had received neoadjuvant therapy.
-
In the metastatic setting, PIK3CA mutation also predicted a worse objective response rate, progression-free survival, and time-to-progression.
Why This Matters
-
PIK3CA mutation occurs frequently in HER2-positive disease (20%–25% of patients), yet the evidence surrounding its significance on cancer or treatment outcomes remains unclear.
-
This meta-analysis suggests PIK3CA mutation does, in fact, affect patient outcomes.
Study Design
-
The researchers searched PubMed, Embase, and the Cochrane Library Central Register of Controlled Trials databases for studies with data on patients with a PIK3CA mutation and various outcome measures in those with HER2-positive breast cancer who had received anti-HER2 therapy.
-
Overall, the researchers identified 43 studies that included 11,099 patients with known PIK3CA mutation status.
Key Results
-
PIK3CA mutation was associated with a lower pathologic complete response rate in the neoadjuvant setting (odds ratio [OR], 0.23; P < .001); the significant association held whether patients received single- or dual-agent anti-HER2 therapy and regardless of hormone receptor status.
-
However, regarding disease-free survival, the authors found no significant association in the adjuvant or neoadjuvant setting.
-
In the metastatic setting, PIK3CA mutation predicted significantly worse objective response rate (OR, 0.26; P < .001), progression-free survival (hazard ratio [HR], 1.28; P = .024) and time-to-progression (HR, 2.27; P < .001); but the authors did not find a significant association between PIK3CA mutation and overall survival.
Limitations
-
The anti-HER2 agents administered in each study and methods of assessment of PIK3CA mutation were not uniform.
-
The number of studies included in several pooled analyses was small.
Disclosures
-
The study was supported by grants from the National Natural Science Foundation of China, the Sun Yat-Sen University Clinical Research Program, the Guangdong Medical Science and Technology Program, and the Tencent Charity Foundation.
-
The authors declared no conflicts of interest.
This is a summary of a preprint research study, “Clinical Significance of PIK3CA Mutation in Primary HER2-Positive Breast Cancer Treated with Anti-HER2 Therapy: A Systematic Review and Meta-Analysis.” The study was published as a preprint and has not been peer reviewed. The full text can be found at ssrn.com.
For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn
Source: Read Full Article
